Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.21 -29.20 (-0.58%) Dow
37,753.31 -45.66 (-0.12%) Nasdaq
15,683.37 -181.88 (-1.15%) Bitcoin USD
62,281.79 -188.76 (-0.30%) CMC Crypto 200
885.54 0.00 (0.00%)
Nuwellis, Inc. (NUWE)
Pre-market:
| Previous close | 0.3350 |
| Open | 0.3350 |
| Bid | 0.3300 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2730 - 0.3500 |
| 52-week range | 0.2700 - 5.7300 |
| Volume | |
| Avg. volume | 567,927 |
| Market cap | 1.889M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
MINNEAPOLIS, April 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow system as part of Nuwellis’ pivotal REVERSE-HF clinical study. “We are excited to study the impact of Aquadex SmartFlow therapy on our heart failure patients who are suffering from severe fluid overload,” s
- GlobeNewswire
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid over
- GlobeNewswire
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital AccountsMINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenu
